Challenges Involved in the Development and Delivery of Abuse-deterrent Formulations of Opioid Analgesics.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Clinical Therapeutics

• Publication date

  2018-02-01

• Fields of study

  Medicine, Business

• Identifiers
  DOI 10.1016/j.clinthera.2018.01.003PMID 29398162
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Current and future development of extended-release, abuse-deterrent opioid formulations in the United States

  2017cited by this paper
• An overview of prodrug technology and its application for developing abuse-deterrent opioids

  2016cited by this paper
• Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.

  2016cited by this paper
• Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain.

  2016cited by this paper
• A Proactive Response to Prescription Opioid Abuse.

  2016cited by this paper
• Hospitalizations Related To Opioid Abuse/Dependence And Associated Serious Infections Increased Sharply, 2002-12.

  2016cited by this paper
• CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016.

  2016cited by this paper
• Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program

  2016cited by this paper
• The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop

  2015cited by this paper
• Abuse-deterrent formulations: transitioning the pharmaceutical market to improve public health and safety

  2015cited by this paper
• The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitability

  2015cited by this paper
• Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.

  2014cited by this paper
• Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US

  2014cited by this paper
• Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment.

  2013cited by this paper
• Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users.

  2013cited by this paper
• Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

  2013cited by this paper
• A review of abuse-deterrent opioids for chronic nonmalignant pain.

  2012cited by this paper
• Research design considerations for clinical studies of abuse‐deterrent opioid analgesics: IMMPACT recommendations

  2012cited by this paper

• Abuse Deterrent Dosage Forms: Approaches, Advantages and Limitations

  2024cites this paper
• Abuse Deterrent Formulations in Constraining the Abuse Potential of Prescription Medicines: A Myth or Truth.

  2021cites this paper
• Abuse-Deterrent Opioids: A Survey of Physician Beliefs, Behaviors, and Psychology

  2021cites this paper
• Abuse-deterrent opioid analgesics: a guide for clinicians.

  2020cites this paper
• Abuse deterrent immediate release film technology (ADRIFT): A novel bilayer film technology for limiting intentional drug abuse.

  2020cites this paper
• The Process of Developing Technological Solutions for Healthcare

  2020cites this paper
• Continuing war on pain: a personalized approach to the therapy with nonsteroidal anti-inflammatory drugs and opioids.

  2019cites this paper
• Mitigation of IV Abuse Through the Use of Abuse‐Deterrent Opioid Formulations: An Overview of Current Technologies

  2019cites this paper
• Abuse Deterrent Immediate Release Egg-Shaped Tablet (Egglets) Using 3D Printing Technology: Quality by Design to Optimize Drug Release and Extraction

  2019cites this paper
• Prevention of Opioid Abuse and Treatment of Opioid Addiction: Current Status and Future Possibilities.

  2019cites this paper
• Efficacy of virtual reality to reduce chronic low back pain: Proof-of-concept of a non-pharmacological approach on pain, quality of life, neuropsychological and functional outcome

  2019cites this paper
• Prevention of Opioid Abuse and Treatment of Opioid Addiction : Current Status and Future Possibilities

  2019cites this paper